Diagonal: Gluing receptor complexes back together

Launched in April, Diagonal is deploying its $128 million in series A funds to use its computational platform to efficiently mine combinations of agonist antibodies, seeking bispecific molecules capable of restoring the signaling of mutant receptor complexes.

Diagonal Therapeutics Inc. aims to treat diseases caused by mutations in receptors that disrupt binding to a partner receptor, reducing downstream signaling. The company’s bispecific antibodies bind two receptor subunits, acting as a glue to bring them together in a specific conformation that enables activation. The goal is a restoration of the receptor complex and its function...